Jacobs Levy Equity Management
CGEM icon

Jacobs Levy Equity Management’s Cullinan Oncology CGEM Stock Holding History

Jacobs Levy Equity Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,755
Closed -$763K – 974
2025
Q4 		$763K Buy
+73,755
New +$665K ﹤0.01% 734
2024
Q3 		– Sell
-98,296
Closed -$1.71M – 969
2024
Q2 		$1.71M Buy
+98,296
New +$2.09M 0.01% 632
2023
Q3 		– Sell
-83,745
Closed -$901K – 979
2023
Q2 		$901K Buy
+83,745
New +$890K 0.01% 715

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Jacobs Levy Equity Management's CGEM Position: Q1 2026 in Review

Jacobs Levy Equity Management sold out of Cullinan Oncology (CGEM) in Q1 2026, closing a stake of 73,755 shares — an estimated $763K sold.

Jacobs Levy Equity Management first reported a position in CGEM in Q2 2023 and held it in 3 quarters. The position peaked at $1.71M in Q2 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Jacobs Levy Equity Management reported no remaining Cullinan Oncology position as of Q1 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 73,755 Cullinan Oncology shares in Q1 2026, an estimated $763K.
  • Jacobs Levy Equity Management first reported a position in Cullinan Oncology in Q2 2023 and held it in 3 quarters.
  • Jacobs Levy Equity Management's Cullinan Oncology position peaked at $1.71M in Q2 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.